Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Allometric Scaling Failures

A focused companion to our animal-vs-human evidence page. This page explains the dose-translation pitfalls in detail — why a rodent dose in mg/kg almost never converts cleanly to a human dose, and why peptides are particularly bad at translating.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

A standard pattern in grey-market peptide content: a rodent study reports a dose of, for example, 10 µg/kg subcutaneous twice daily. An online source multiplies this by a 70 kg body weight to derive a 700 µg twice-daily “human dose.” This is wrong for several independent reasons. This page enumerates them.

Body weight is the wrong scaling variable

Allometric scaling — relating physiological variables across species — uses body-surface area or metabolic rate, not body weight. Smaller animals have higher per-kg metabolic rate, more rapid clearance, and proportionally smaller plasma volumes. The FDA's published Guidance for Industry on initial human dose selection uses a Human Equivalent Dose (HED) calculated as the animal dose divided by a species-specific factor — for example, rat dose × 0.16 to estimate the HED in mg/kg.

A 10 mg/kg dose in a rat does not equate to 700 mg in a 70 kg human. By HED calculation it equates to approximately 1.6 mg/kg — i.e. ~112 mg, an order of magnitude less than the naive bodyweight extrapolation. This is the conservative no-other-information starting estimate, not a clinical dose.

Receptor distribution differs between species

Allometric scaling assumes the receptor target is comparably distributed across species. For many peptide targets, this is false:

  • GLP-1 receptor expression differs in density and tissue distribution between rodents and humans, contributing to the different magnitude of weight effects observed across species.
  • Melanocortin receptors have substantially different tissue distributions in mice vs humans. Mouse models of obesity, pigmentation, and sexual behaviour driven by MC4R activation do not all translate cleanly.
  • Ghrelin receptor (GHSR-1a) central expression differs across species; the rodent appetite response to GHRPs does not predict the human magnitude.
  • Thymic-peptide targets — thymic involution patterns differ markedly between species, complicating the age-related modelling.

Pharmacokinetics differ — sometimes by orders of magnitude

Plasma half-life, protein binding, and clearance pathways all diverge across species:

  • Native peptide half-life is typically minutes in all mammals — but the per-mg clearance rate scales with metabolic rate, not body weight.
  • Fatty-acid-conjugated peptides (semaglutide, tirzepatide) depend on albumin binding for their long half-life. Albumin concentration is broadly comparable across mammals, but binding affinity for any given conjugate can differ.
  • DPP-IV cleavage rate differs between species and across the same peptide's sequence variants.
  • Renal clearance for peptides eliminated through glomerular filtration scales with kidney size, which is not linear with body weight.

Immunogenicity profiles diverge

A peptide that is non-immunogenic in rodents can be substantially more immunogenic in humans, and vice versa. Mice often do not produce neutralising antibodies to human-sequence peptides on chronic dosing; humans do. This is a particularly important constraint for the chronic-dosing translation of mitochondrial and bioregulator peptides. See immunogenicity explained.

Why peptides translate especially poorly

Several class-specific factors compound the general rodent-to- human translation problem for peptides:

  • Route of administration matters more. A peptide delivered subcutaneously in a rat vs intraperitoneally vs orally produces very different exposure profiles; the published literature is inconsistent about which route was studied.
  • Tissue penetration is harder to extrapolate.Peptide tissue distribution depends on molecular size, charge, and active transport — all of which vary across species.
  • Single-laboratory effects. Many peptide findings are concentrated in one or two laboratories with specific handling and formulation protocols. Translation assumes the formulation reproduces — it often doesn't.
  • Disease-model mismatch. A chemically-induced rodent injury model does not match human chronic pathology. Even if dose translation worked, the indication wouldn't.

The first-in-human approach

Properly conducted drug development handles this by:

  1. Calculating the Human Equivalent Dose (HED) from the most sensitive species' No Observed Adverse Effect Level (NOAEL).
  2. Applying a 10× safety factor to derive a Maximum Recommended Starting Dose (MRSD).
  3. Beginning Phase I dosing well below that, with small single-ascending-dose cohorts and intensive monitoring.
  4. Iteratively titrating across multiple cohorts to determine a tolerated and pharmacologically active human dose.

This process can take years and millions of dollars per compound. It is what produces a clinically-meaningful human dose. Online “mg/kg × bodyweight” calculations are not a substitute for it.

What this means for reading peptide content

When a source describes “research-protocol dosing” for an unapproved peptide, ask: was this dose derived from a registered human clinical trial, or extrapolated from animal data by bodyweight? Most online doses for unapproved compounds are the latter. They are not safe starting estimates; they are not clinical doses; they have not been through the process above. On PeptideStacks we report doses in study context only, with the species and route of the underlying study made explicit.

Related